Targets › CAG
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Apr 2028.
Open in Phaseline: the race on CAG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vico Therapeutics B. V. | VO659 Antisense oligonucleotide targeting CAG repeats | CAG | Phase 1 | Spinocerebellar Ataxia Type 1 | Apr 2028 |
Spinocerebellar Ataxia Type 1 (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.